Year: 2023
Type: editorial
Abstract: Optimal management of Multiple Myeloma (MM), a disorder of clonal malignant plasmacells (PCs), is hampered the lack of strategies to treat specific subsets of patients.Despite genetic, epigenetic, and mutational heterogeneity, every patient still receives similar regimens without accounting for this variability.This can lead to unsatisfactory or short-lasting responses especially in the relapsed settings or in patients with high-risk chromosomal abnormalities such as t(4;14), 1q21+, or deletion(17p) [1].MM cells express on their surface a variety of antigens, which help to discern normal reactive PCs from malignant MM cells [2].These antigens are also targets for monoclonal antibodies, bispecific engagers, or chimeric T/NK cellular therapy [3,4].Among them, there is CD56 or NCAM1 (Neuronal Cell adhesion molecule 1), Cancer Institute (1K08CA263476-01A1 to FC).
Source: Oncotarget
Authors: Francesca Cottini, Don Benson
Institution: The Ohio State University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4318263286